semaglutide phase 1 as a GLP-1 Agonist: A Breakthrough in Obesity Treatment Semaglutide 1.75mg - 4 injections

Lancet Diabetes & Endocrinology , 7 (11), 834844

66% of adults taking Wegovy lost 10% or more weight, compared to 12% taking placebo

GLP-1 medications slow the movement of food through the digestive tract, which can affect the balance of bacteria in the gut microbiome over time

[Tirzepatide] topped the charts in improving [most] cardiometabolic parameters, Majety said

Overall, research studies show that the results of surgery are disappointing (Bressler 2004)

Data availability The data that support the findings of this study are located in controlled access data storage at the Haseki Training and Research Hospital, Istanbul